adalimumab (preferred products) — Highmark
Hidradenitis Suppurativa (HS)
Initial criteria
- age ≥ 12 years
- diagnosis of moderate to severe HS
- prescribed by or in consultation with a dermatologist
Reauthorization criteria
- member has demonstrated disease stability or a beneficial response to therapy